Novartis AG acquired Kedalion Therapeutics and its AcuStream technology, a novel device to improve the Novartis ophthalmic portfolio.
AbbVie Inc. declared the U.S. Food and Drug Administration (FDA) approval of VUITY, a pilocarpine HCl ophthalmic solution of 1.25 % used for the treatment of presbyopia that affects 128 million Americans.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?